Head And Neck Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Head And Neck Cancer – Pipeline Review, H1 2017’, provides an overview of the Head And Neck Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer

The report reviews pipeline therapeutics for Head And Neck Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Head And Neck Cancer therapeutics and enlists all their major and minor projects

The report assesses Head And Neck Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

4SC AG

AB Science SA

AbbVie Inc

Abion Inc

Accelerated Pharma Inc

Acceleron Pharma Inc

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advaxis Inc

Advenchen Laboratories LLC

Affimed GmbH

Altor BioScience Corp

Ambrx Inc

amcure GmbH

Amgen Inc

arGEN-X BV

ArQule Inc

Array BioPharma Inc

Aspyrian Therapeutics Inc

Astellas Pharma Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

ATLAB Pharma SAS

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Benitec Biopharma Ltd

Beta Pharma Inc

Bexion Pharmaceuticals LLC

BioDiem Ltd

Biomics Biotechnologies Co Ltd

Bionovis SA

BioNTech AG

Biotest AG

Biothera Pharmaceutical Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

CBT Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

Cellceutix Corp

Celldex Therapeutics Inc

Celprogen Inc

Centrose LLC

Corvus Pharmaceuticals Inc

Cristal Therapeutics BV

Critical Outcome Technologies Inc

CytImmune Sciences Inc

Daiichi Sankyo Company Ltd

Denceptor Therapeutics Ltd

DNJ Pharma Inc

Dynavax Technologies Corp

Eisai Co Ltd

Eleven Biotherapeutics Inc

Eli Lilly and Company

Etubics Corp

Eureka Therapeutics Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Forty Seven Inc

Fujifilm Corp

G&E Herbal Biotechnology Co Ltd

Galectin Therapeutics Inc

Genelux Corp

GeneSegues Inc

Genexine Inc

Genmab A/S

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Gliknik Inc

Glycotope GmbH

Griffith University

Hanmi Pharmaceuticals Co Ltd

Hookipa Biotech AG

Horizon Pharma Plc

Hutchison China MediTech Ltd

Ignyta Inc

Immunocore Ltd

Immunomedics Inc

Immunovaccine Inc

Immunovative Therapies Ltd

Incyte Corp

Infinity Pharmaceuticals Inc

Innate Pharma SA

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

Ipsen SA

IRX Therapeutics Inc

ISA Pharmaceuticals BV

ISU ABXIS Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Kite Pharma Inc

Kura Oncology Inc

Laboratoires Pierre Fabre SA

LATITUDE Pharmaceuticals Inc

Lion Biotechnologies Inc

Loxo Oncology Inc

Lytix Biopharma AS

Mabion SA

MacroGenics Inc

Marsala Biotech Inc

Mateon Therapeutics Inc

MaxiVAX SA

Meabco A/S

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Moleculin Biotech Inc

Molplex Ltd

NanoCarrier Co Ltd

NantKwest Inc

Natco Pharma Ltd

NeoImmuneTech Inc

Neonc Technologies Inc

Neumedicines Inc

Northwest Biotherapeutics Inc

Novartis AG

Noxopharm Ltd

Oncobiologics Inc

Oncolys BioPharma Inc

Onconova Therapeutics Inc

OncoSec Medical Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Oryx GmbH & Co KG

PCI Biotech Holding ASA

PDS Biotechnology Corp

Pfizer Inc

Pharma Mar SA

Pique Therapeutics

PlantForm Corp

Plexxikon Inc

PNP Therapeutics Inc

Profectus BioSciences Inc

Provectus Biopharmaceuticals Inc

PsiOxus Therapeutics Ltd

R Pharm

Redx Pharma Plc

Reliance Life Sciences Pvt Ltd

Sareum Holdings Plc

Selecta Biosciences Inc

Shionogi & Co Ltd

Sierra Oncology Inc

Sillajen Biotherapeutics

Sinil Pharmaceutical Co Ltd

Sorrento Therapeutics Inc

Sound Pharmaceuticals Inc

SuviCa Inc

Symphogen A/S

SynCore Biotechnology Co Ltd

Taiwan Liposome Company Ltd

Takara Bio Inc

Takis Srl

Tessa Therapeutics Pte Ltd

Theravectys SA

Threshold Pharmaceuticals Inc

Tolero Pharmaceuticals Inc

Transgene SA

UbiVac LLC

Vaccibody AS

VasGene Therapeutics Inc

Vault Pharma Inc

Vaxeal Holding SA

VentiRx Pharmaceuticals Inc

Viracta Therapeutics Inc

Yabao Pharmaceutical Group Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Head And Neck Cancer - Overview 10

Head And Neck Cancer - Therapeutics Development 11

Head And Neck Cancer - Therapeutics Assessment 51

Head And Neck Cancer - Companies Involved in Therapeutics Development 75

Head And Neck Cancer - Drug Profiles 167

Head And Neck Cancer - Dormant Projects 1190

Head And Neck Cancer - Discontinued Products 1200

Head And Neck Cancer - Product Development Milestones 1202

Appendix 1211

List of Tables

List of Tables

Number of Products under Development for Head And Neck Cancer, H1 2017 46

Number of Products under Development by Companies, H1 2017 48

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 49

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 50

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 51

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 52

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 53

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 54

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 55

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 56

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 57

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 58

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 59

Number of Products under Development by Universities/Institutes, H1 2017 60

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 62

Products under Development by Companies, H1 2017 63

Products under Development by Companies, H1 2017 (Contd..1), H1 2017 64

Products under Development by Companies, H1 2017 (Contd..2), H1 2017 65

Products under Development by Companies, H1 2017 (Contd..3), H1 2017 66

Products under Development by Companies, H1 2017 (Contd..4), H1 2017 67

Products under Development by Companies, H1 2017 (Contd..5), H1 2017 68

Products under Development by Companies, H1 2017 (Contd..6), H1 2017 69

Products under Development by Companies, H1 2017 (Contd..7), H1 2017 70

Products under Development by Companies, H1 2017 (Contd..8), H1 2017 71

Products under Development by Companies, H1 2017 (Contd..9), H1 2017 72

Products under Development by Companies, H1 2017 (Contd..10), H1 2017 73

Products under Development by Companies, H1 2017 (Contd..11), H1 2017 74

Products under Development by Companies, H1 2017 (Contd..12), H1 2017 75

Products under Development by Companies, H1 2017 (Contd..13), H1 2017 76

Products under Development by Companies, H1 2017 (Contd..14), H1 2017 77

Products under Development by Companies, H1 2017 (Contd..15), H1 2017 78

Products under Development by Companies, H1 2017 (Contd..16), H1 2017 79

Products under Development by Companies, H1 2017 (Contd..17), H1 2017 80

Products under Development by Companies, H1 2017 (Contd..18), H1 2017 81

Products under Development by Companies, H1 2017 (Contd..19), H1 2017 82

Products under Development by Universities/Institutes, H1 2017 83

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 84

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 85

Number of Products by Stage and Target, H1 2017 87

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 88

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 89

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 90

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 91

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 92

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 93

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 94

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017 95

Number of Products by Stage and Mechanism of Action, H1 2017 97

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 98

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 99

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 100

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 101

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 102

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 103

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 104

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017 105

Number of Products by Stage and Route of Administration, H1 2017 107

Number of Products by Stage and Molecule Type, H1 2017 109

Head And Neck Cancer – Pipeline by 3SBio Inc, H1 2017 110

Head And Neck Cancer – Pipeline by 4SC AG, H1 2017 110

Head And Neck Cancer – Pipeline by AB Science SA, H1 2017 111

Head And Neck Cancer – Pipeline by AbbVie Inc, H1 2017 111

Head And Neck Cancer – Pipeline by Abion Inc, H1 2017 112

Head And Neck Cancer – Pipeline by Accelerated Pharma Inc, H1 2017 112

Head And Neck Cancer – Pipeline by Acceleron Pharma Inc, H1 2017 113

Head And Neck Cancer – Pipeline by Adaptimmune Therapeutics Plc, H1 2017 113

Head And Neck Cancer – Pipeline by Aduro BioTech Inc, H1 2017 114

Head And Neck Cancer – Pipeline by Advaxis Inc, H1 2017 114

Head And Neck Cancer – Pipeline by Advenchen Laboratories LLC, H1 2017 115

Head And Neck Cancer – Pipeline by Affimed GmbH, H1 2017 115

Head And Neck Cancer – Pipeline by Altor BioScience Corp, H1 2017 116

Head And Neck Cancer – Pipeline by Ambrx Inc, H1 2017 116

Head And Neck Cancer – Pipeline by amcure GmbH, H1 2017 117

Head And Neck Cancer – Pipeline by Amgen Inc, H1 2017 117

Head And Neck Cancer – Pipeline by arGEN-X BV, H1 2017 118

Head And Neck Cancer – Pipeline by ArQule Inc, H1 2017 118

Head And Neck Cancer – Pipeline by Array BioPharma Inc, H1 2017 119

Head And Neck Cancer – Pipeline by Aspyrian Therapeutics Inc, H1 2017 119

Head And Neck Cancer – Pipeline by Astellas Pharma Inc, H1 2017 120

Head And Neck Cancer – Pipeline by AstraZeneca Plc, H1 2017 121

Head And Neck Cancer – Pipeline by Atara Biotherapeutics Inc, H1 2017 122

Head And Neck Cancer – Pipeline by ATLAB Pharma SAS, H1 2017 122

Head And Neck Cancer – Pipeline by AVEO Pharmaceuticals Inc, H1 2017 123

Head And Neck Cancer – Pipeline by Bayer AG, H1 2017 124

Head And Neck Cancer – Pipeline by BeiGene Ltd, H1 2017 124

Head And Neck Cancer – Pipeline by Benitec Biopharma Ltd, H1 2017 125

Head And Neck Cancer – Pipeline by Beta Pharma Inc, H1 2017 125

Head And Neck Cancer – Pipeline by Bexion Pharmaceuticals LLC, H1 2017 126

Head And Neck Cancer – Pipeline by BioDiem Ltd, H1 2017 126

Head And Neck Cancer – Pipeline by Biomics Biotechnologies Co Ltd, H1 2017 127

Head And Neck Cancer – Pipeline by Bionovis SA, H1 2017 127

Head And Neck Cancer – Pipeline by BioNTech AG, H1 2017 128

Head And Neck Cancer – Pipeline by Biotest AG, H1 2017 128

Head And Neck Cancer – Pipeline by Biothera Pharmaceutical Inc, H1 2017 129

Head And Neck Cancer – Pipeline by Boehringer Ingelheim GmbH, H1 2017 129

Head And Neck Cancer – Pipeline by Boston Biomedical Inc, H1 2017 130

Head And Neck Cancer – Pipeline by Bristol-Myers Squibb Company, H1 2017 130

Head And Neck Cancer – Pipeline by CBT Pharmaceuticals Inc, H1 2017 131

Head And Neck Cancer – Pipeline by Celgene Corp, H1 2017 131

Head And Neck Cancer – Pipeline by Cell Medica Ltd, H1 2017 132

Head And Neck Cancer – Pipeline by Cellceutix Corp, H1 2017 132

Head And Neck Cancer – Pipeline by Celldex Therapeutics Inc, H1 2017 133

Head And Neck Cancer – Pipeline by Celprogen Inc, H1 2017 133

Head And Neck Cancer – Pipeline by Centrose LLC, H1 2017 134

Head And Neck Cancer – Pipeline by Corvus Pharmaceuticals Inc, H1 2017 134

Head And Neck Cancer – Pipeline by Cristal Therapeutics BV, H1 2017 135

Head And Neck Cancer – Pipeline by Critical Outcome Technologies Inc, H1 2017 135

Head And Neck Cancer – Pipeline by CytImmune Sciences Inc, H1 2017 136

Head And Neck Cancer – Pipeline by Daiichi Sankyo Company Ltd, H1 2017 136

Head And Neck Cancer – Pipeline by Denceptor Therapeutics Ltd, H1 2017 137

Head And Neck Cancer – Pipeline by DNJ Pharma Inc, H1 2017 137

Head And Neck Cancer – Pipeline by Dynavax Technologies Corp, H1 2017 138

Head And Neck Cancer – Pipeline by Eisai Co Ltd, H1 2017 138

Head And Neck Cancer – Pipeline by Eleven Biotherapeutics Inc, H1 2017 139

Head And Neck Cancer – Pipeline by Eli Lilly and Company, H1 2017 139

Head And Neck Cancer – Pipeline by Etubics Corp, H1 2017 140

Head And Neck Cancer – Pipeline by Eureka Therapeutics Inc, H1 2017 140

Head And Neck Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 141

Head And Neck Cancer – Pipeline by Five Prime Therapeutics Inc, H1 2017 141

Head And Neck Cancer – Pipeline by Forty Seven Inc, H1 2017 142

Head And Neck Cancer – Pipeline by Fujifilm Corp, H1 2017 142

Head And Neck Cancer – Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017 143

Head And Neck Cancer – Pipeline by Galectin Therapeutics Inc, H1 2017 143

Head And Neck Cancer – Pipeline by Genelux Corp, H1 2017 144

Head And Neck Cancer – Pipeline by GeneSegues Inc, H1 2017 144

Head And Neck Cancer – Pipeline by Genexine Inc, H1 2017 145

Head And Neck Cancer – Pipeline by Genmab A/S, H1 2017 145

Head And Neck Cancer – Pipeline by GlaxoSmithKline Plc, H1 2017 146

Head And Neck Cancer – Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017 147

Head And Neck Cancer – Pipeline by Gliknik Inc, H1 2017 147

Head And Neck Cancer – Pipeline by Glycotope GmbH, H1 2017 148

Head And Neck Cancer – Pipeline by Griffith University, H1 2017 148

Head And Neck Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 149

Head And Neck Cancer – Pipeline by Hookipa Biotech AG, H1 2017 149

Head And Neck Cancer – Pipeline by Horizon Pharma Plc, H1 2017 150

Head And Neck Cancer – Pipeline by Hutchison China MediTech Ltd, H1 2017 150

Head And Neck Cancer – Pipeline by Ignyta Inc, H1 2017 151

Head And Neck Cancer – Pipeline by Immunocore Ltd, H1 2017 151

Head And Neck Cancer – Pipeline by Immunomedics Inc, H1 2017 152

Head And Neck Cancer – Pipeline by Immunovaccine Inc, H1 2017 152

Head And Neck Cancer – Pipeline by Immunovative Therapies Ltd, H1 2017 153

Head And Neck Cancer – Pipeline by Incyte Corp, H1 2017 153

Head And Neck Cancer – Pipeline by Infinity Pharmaceuticals Inc, H1 2017 154

Head And Neck Cancer – Pipeline by Innate Pharma SA, H1 2017 154

Head And Neck Cancer – Pipeline by Inovio Pharmaceuticals Inc, H1 2017 155

Head And Neck Cancer – Pipeline by InteRNA Technologies BV, H1 2017 155

Head And Neck Cancer – Pipeline by Ipsen SA, H1 2017 156

Head And Neck Cancer – Pipeline by IRX Therapeutics Inc, H1 2017 156

Head And Neck Cancer – Pipeline by ISA Pharmaceuticals BV, H1 2017 157

Head And Neck Cancer – Pipeline by ISU ABXIS Co Ltd, H1 2017 157

Head And Neck Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 158

Head And Neck Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017 158

Head And Neck Cancer – Pipeline by Johnson & Johnson, H1 2017 159

Head And Neck Cancer – Pipeline by Juno Therapeutics Inc, H1 2017 159

Head And Neck Cancer – Pipeline by Kite Pharma Inc, H1 2017 160

Head And Neck Cancer – Pipeline by Kura Oncology Inc, H1 2017 160

Head And Neck Cancer – Pipeline by Laboratoires Pierre Fabre SA, H1 2017 161

Head And Neck Cancer – Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017 161

Head And Neck Cancer – Pipeline by Lion Biotechnologies Inc, H1 2017 162

Head And Neck Cancer – Pipeline by Loxo Oncology Inc, H1 2017 162

Head And Neck Cancer – Pipeline by Lytix Biopharma AS, H1 2017 163

Head And Neck Cancer – Pipeline by Mabion SA, H1 2017 163

Head And Neck Cancer – Pipeline by MacroGenics Inc, H1 2017 164

Head And Neck Cancer – Pipeline by Marsala Biotech Inc, H1 2017 164

Head And Neck Cancer – Pipeline by Mateon Therapeutics Inc, H1 2017 165

Head And Neck Cancer – Pipeline by MaxiVAX SA, H1 2017 165

Head And Neck Cancer – Pipeline by Meabco A/S, H1 2017 166

Head And Neck Cancer – Pipeline by MedImmune LLC, H1 2017 167

Head And Neck Cancer – Pipeline by Merck & Co Inc, H1 2017 168

Head And Neck Cancer – Pipeline by Merck KGaA, H1 2017 169

Head And Neck Cancer – Pipeline by Millennium Pharmaceuticals Inc, H1 2017 169

Head And Neck Cancer – Pipeline by Mirati Therapeutics Inc, H1 2017 170

Head And Neck Cancer – Pipeline by Moleculin Biotech Inc, H1 2017 170

Head And Neck Cancer – Pipeline by Molplex Ltd, H1 2017 171

Head And Neck Cancer – Pipeline by NanoCarrier Co Ltd, H1 2017 171

Head And Neck Cancer – Pipeline by NantKwest Inc, H1 2017 172

Head And Neck Cancer – Pipeline by Natco Pharma Ltd, H1 2017 172

Head And Neck Cancer – Pipeline by NeoImmuneTech Inc, H1 2017 173

Head And Neck Cancer – Pipeline by Neonc Technologies Inc, H1 2017 173

Head And Neck Cancer – Pipeline by Neumedicines Inc, H1 2017 174

Head And Neck Cancer – Pipeline by Northwest Biotherapeutics Inc, H1 2017 174

Head And Neck Cancer – Pipeline by Novartis AG, H1 2017 175

Head And Neck Cancer – Pipeline by Noxopharm Ltd, H1 2017 175

Head And Neck Cancer – Pipeline by Oncobiologics Inc, H1 2017 176

Head And Neck Cancer – Pipeline by Oncolys BioPharma Inc, H1 2017 176

Head And Neck Cancer – Pipeline by Onconova Therapeutics Inc, H1 2017 177

List of Figures

List of Figures

Number of Products under Development for Head And Neck Cancer, H1 2017 46

Number of Products under Development by Companies, H1 2017 47

Number of Products under Development by Universities/Institutes, H1 2017 60

Number of Products by Top 10 Targets, H1 2017 86

Number of Products by Stage and Top 10 Targets, H1 2017 86

Number of Products by Top 10 Mechanism of Actions, H1 2017 96

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 96

Number of Products by Top 10 Routes of Administration, H1 2017 106

Number of Products by Stage and Top 10 Routes of Administration, H1 2017 106

Number of Products by Top 10 Molecule Types, H1 2017 108

Number of Products by Stage and Top 10 Molecule Types, H1 2017 108

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports